Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET
Harvard Bioscience (NASDAQ: HBIO) will report financial results for the quarter ended September 30, 2025 before market open on November 6, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (NASDAQ: HBIO) will report financial results for the quarter ended September 30, 2025 before market open on November 6, 2025. The company will host a conference call to discuss results at 8:00 AM Eastern Time on the same day.
Participants who wish to ask questions must register to receive dial-in numbers and a unique PIN. An audio-only webcast will be available via the company’s Investor Relations events and presentations page. The earnings release and related slide presentation will be posted in the Investor Relations section.
Details
News Market Reaction – HBIO
On Oct 30, the day this news came out, HBIO closed 41.10% above the previous close.
Data tracked by StockTitan Argus for the Oct 30 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.